Surges in COVID-19 incidence in countries with high vaccination coverage - RKI
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
COVID-19 Containment Measures, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage COVID- CONTAINMENT MEASURES ANALYSIS, ISSUE ) Surges in COVID-19 incidence in countries with high vaccination coverage Evidence-Based Public Health (ZIG 2) | Center for International Health Protection (ZIG) Robert Koch Institute
1 COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
Surges in COVID-19 incidence in countries with high vaccination coverage
Robert Koch-Institute, 2021
Funding
This report was developed under the project Analysis of international epidemiological data and response
measures, a project funded by the German Federal Ministry of Health (BMG).
Authors
Thurid Bahr, Evidence-Based Public Health, Centre for International Health Protection
Nina Klein, Evidence-Based Public Health, Centre for International Health Protection
Seth Kofi Abrokwa, Evidence-Based Public Health, Centre for International Health Protection
Lothar H. Wieler, President
Johanna Hanefeld, Centre for International Health Protection
Charbel El-Bcheraoui, Evidence-Based Public Health, Centre for International Health Protection
Acknowledgements
The authors gratefully acknowledge Luisa Denkel, Angela Fehr and the Public Health Intelligence team for
their valuable input and feedback on this report.
The icons on pages 5, 7, 8, 10 and 15 stem from https://allthefreestock.com.
Suggested Citation
Bahr, T., Klein, N., Abrokwa, S. K., Wieler, L. H., Hanefeld, J. and El-Bcheraoui, C., 2021. Surges in COVID-19
incidence in countries with high vaccination coverage. Report. COVID-19 Containment Measures Analysis,
Issue 5, Robert Koch Institute, Berlin.
Disclaimer
The content of this report expresses the opinions of its authors and does not necessarily represent the views of
the Robert Koch Institute.2 COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
Summary
Surges in incidence in countries with high vaccination coverage have concerned decision makers. This report
covers five countries that have experienced such surges despite high vaccination coverage: Bahrain, Chile,
Seychelles, the United Kingdom and Uruguay. Germany is included in the report to enable comparison. The
report describes select epidemiological indicators, maps the COVID-19 containment measures in place and
describes vaccination rollout in the countries between 1 March and 29 June 2021.
Reliable data on what drove or continues to drive surges is not available for most countries. In particular, the
following kinds of data are not available for most of the five countries in sufficient quality:
Age distribution of COVID-19 cases.
Vaccination status of COVID-19 cases.
High-quality genomic surveillance data on variants of concern.
Surges are possibly due to a combination of factors. These include:
Premature loosening of COVID-19 containment measures.
Reduced compliance with physical distancing requirements, including by individuals with incomplete
vaccination coverage.
Spread of variants of concern.
Surges in incidence provide important lessons in COVID-19 containment:
Unvaccinated population groups remain vulnerable even in countries with higher vaccination coverage.
COVID-19 containment measures should be upheld during vaccination campaigns, including to protect
unvaccinated and vulnerable individuals.
The recent surges in incidence have also provided insights regarding vaccine effectiveness:
The effectiveness of distributed vaccines in the six countries is generally not significantly reduced by
circulating variants of concern.
According to media reports, the majority of new cases during periods of surging incidence occurred in
unvaccinated individuals or in those who were not yet fully vaccinated.
Germany could consider the following recommendations:
Countries experiencing surges in COVID-19 incidence should investigate the age distribution and
vaccination status of cases. This could provide them with the evidence needed to adopt suitable
countermeasures. Countries should also share these data internationally to inform decision-making.
National vaccination campaigns should strive to reach unvaccinated individuals. Continued high incidence
worldwide entails a continued risk that further variants of concern may emerge and spread. Therefore,
vaccination campaigns should also be considered a global effort.
If countries lack evidence on variants of concern due to low genomic surveillance capacities, these
countries should be supported in building up that capacity.3 COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
Zusammenfassung
Ansteigende Fallzahlen in Ländern mit hohen Durchimpfungsraten werden von Entscheidungstragenden mit
Besorgnis beobachtet. Dieser Bericht befasst sich mit fünf Ländern, die einen solchen Anstieg trotz hoher
Durchimpfungsraten verzeichnen: Bahrain, Chile, die Seychellen, Uruguay und das Vereinigte Königreich. Über
Deutschland wird ebenfalls berichtet, um einen Vergleich zu den anderen Ländern zu ermöglichen. Der Bericht
beschreibt ausgewählte epidemiologische Indikatoren, COVID-19 Eindämmungsmaßnahmen und
Impfkampagnen in den Ländern zwischen dem 1. März und 29. Juni 2021.
Verlässliche Daten dazu, was Fallanstiege hervorgerufen haben könnte, sind für die fünf Länder zumeist nicht
verfügbar. Insbesondere fehlen die folgenden Daten in ausreichender Qualität:
Altersverteilung von COVID-19 Fällen.
Impfstatus von COVID-19 Fällen.
Surveillancedaten hoher Qualität zu besorgniserregenden Virusvarianten.
Ansteigende Fallzahlen sind vermutlich auf eine Kombination von Faktoren zurückzuführen. Diese beinhalten:
Verfrühte Lockerung von COVID-19 Eindämmungsmaßnahmen.
Verminderte Befolgung von Abstandsregeln, auch durch Personen mit unvollständigem Impfschutz.
Ausbreitung von Variants of Concern.
Ansteigende Fallzahlen vermitteln wichtige Lektionen für die Eindämmung von COVID-19:
Ungeimpfte Bevölkerungsgruppen sind selbst in Ländern mit hoher Durchimpfungsrate weiterhin
Risiken ausgesetzt.
COVID-19 Eindämmungsmaßnahmen sollten während Impfkampagnen aufrechterhalten werden, um
ungeimpfte Personen und solche aus Risikogruppen zu schützen.
Ansteigende Fallzahlen verweisen auch auf Erkenntnisse zur Impfstoffeffektivität:
Die Effektivität der in den sechs Ländern verimpften Impfstoffe wird durch die zirkulierenden Variants of
Concern nicht signifikant reduziert.
Medienberichten zufolge war die Mehrheit der in den fünf Ländern kürzlich infizierten Personen
entweder ungeimpft oder nicht vollständig geimpft.
Deutschland könnte die folgenden Empfehlungen in Erwägung ziehen:
Länder mit ansteigenden Fallzahlen und hohen Durchimpfungsraten sollten die Altersverteilung und den
Impfstatus der auftretenden Fälle beobachten. Diese Daten können dazu genutzt werden, angemessene
Eindämmungsmaßnahmen einzuleiten. Die Länder sollten diese Daten auch international teilen und so
eine Berücksichtigung der Daten bei der Entscheidungsfindung ermöglichen.
Nationale Impfkampagnen sollten darauf abzielen, ungeimpfte Personen zu erreichen. Fortdauernde
hohe Inzidenzen weltweit bergen das Risiko der Entstehung und Verbreitung weiterer
besorgniserregender Virusvarianten. Der Erfolg von Impfkampagnen sollte daher auch als globales
Anliegen gesehen werden.
Falls es Ländern aufgrund von geringer Surveillancekapazität an Daten zu zirkulierenden
besorgniserregenden Virusvarianten mangelt, so sollten diese Länder beim Aufbau dieser Kapazität
unterstützt werden.4 COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
1. Problem Statement
Despite succeeding at vaccinating large parts of their population against the SARS-COV-2 virus in a short time,
some countries have experienced surges in incidence. To understand this dynamic, this report tracks select
epidemiological indicators, maps the COVID-19 containment measures in place, and describes vaccination
rollout in Bahrain, Chile, Germany, Seychelles, the United Kingdom and Uruguay between 1 March and 29 June
2021. Germany is not currently experiencing a surge in incidence and is included in this report for comparison
purposes. Looking at the context in which increases in incidence occurred despite high vaccination coverage can
help guide decision makers on adapting their COVID-19 containment measures and de-escalation plans.
2. Weekly COVID-19 incidence, deaths and vaccination coverage (2nd dose) in Bahrain, Chile, Germany,
Seychelles, the United Kingdom and Uruguay, weeks 9 – 25, 2021 (Figure 1)
As of late June 2021, Weekly COVID-19 incidence per 100,000 population is decreasing in Bahrain, Chile,
Germany, Seychelles and Uruguay. Weekly death rates per 100,000 population are decreasing in Bahrain,
Germany and Uruguay and increasing in Chile, Seychelles and the United Kingdom. Full vaccination coverage
is at just under 40% and higher in the countries.COVID-19 Containment Measures, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage Figure 1: Weekly COVID-19 incidence, deaths and full vaccination coverage (2nd dose) in Bahrain, Chile, Germany, Seychelles, the United Kingdom and Uruguay, weeks 9-2021 – 25-2021
COVID-19 Containment Measures, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage 3. Vaccination Coverage and National Vaccination Campaigns 3.1 Full Vaccination coverage in Bahrain, Chile, Germany, Seychelles, the United Kingdom and Uruguay, 1 March – 27 June 2021 (Figure 1): 2nd Dose – Between 1 March and 27 June 2021, the share of the population that received its second COVID-19 vaccine dose increased from 0 to 45% in Uruguay, from 2 to 48% in the United Kingdom, from 3 to 35% in Germany, from 3 to 50% in Chile (1 March to 20 June), from 12 to 57% in Bahrain and from 25 to 68% in Seychelles.[1, 2] 3.2 Vaccination access in Bahrain, Chile, Germany, Seychelles, the United Kingdom and Uruguay, 1 March – 29 June 2021 (Table 1): Administered vaccines – In three out of four countries experiencing surges in incidence and for which data on predominantly administered vaccine types was available, the Sinopharm and Sinovac vaccines were predominantly administered. Vaccine effectiveness – The administered vaccine types mostly maintain their effectiveness against circulating virus variants against symptomatic disease, severe disease, hospitalization and death. There is emerging evidence on the effectiveness of vaccines against transmission.[3] However, effectiveness requires taking the full course of vaccine doses and requires some time to lapse between completion of the course for antibodies to build up. ECDC reports that receiving only a first dose of a two-dose vaccination course provides less protection against infection with variant of concern (VOC) Delta than against other VOCs. This holds regardless of vaccine type. Yet receiving both doses offers nearly the same level of protection against Delta as against other VOCs.[4] Scientific, publicly available evidence is scarce on the Sinovac and Sinopharm vaccines, in particular peer reviewed publication of data on phase 3 trials and evidence from population-based studies is lacking.[5, 6] The World Health Organization granted Emergency Use to the Sinopharm and Sinovac vaccines in early May and early July, based on evidence from vaccine trials. WHO holds Sinovac to be effective against infection and symptomatic disease caused by the Delta VOC (Table 1). [3, 7-9]. Study results from Chile showed that the Sinovac vaccine had little effectiveness immediately following just a single dose, with rising effectiveness after two and three weeks following a single dose.[10, 11] Vaccine access – Currently, the six countries universally offer vaccinations to their populations. Bahrain vaccinates anyone aged 12 and older. Germany vaccinates adolescents aged 12 and older with specific co- morbidities (e.g. chronic lung diseases with persisting impairment of lung function), work-related high risk of exposure as well as when living with people with a high risk who cannot be vaccinated themselves.[12] In addition, the country vaccinates all adults aged 18 and older. The remaining countries also vaccinate anyone aged 18 and older.
COVID-19 Containment Measures, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
Table 1: COVID-19 Vaccination Campaigns in Bahrain, Chile, Germany, Seychelles, the United Kingdom and Uruguay, 1 March 2020 – 29 June 2021
Administered Vaccines Vaccine Effectiveness Vaccine Access
Oxford/AstraZeneca - Currently no evidence on effectiveness of Sinopharm vaccine against circulating Anyone aged 12+[14]
Pfizer/BioNTech variants[8]
Bahrain
Sinopharm/Beijing + Currently no evidence that effectiveness of other administered vaccines may be Pfizer/BioNTech “booster dose” for first responders, those
Sputnik V[13] significantly reduced by predominantly circulating variants[3] aged 50 and over and those with comorbidities who
received two doses of Sinopharm six months ago[15, 16]
79% Sinovac - Limited evidence of potentially very small effectiveness shortly after first Sinovac Anyone aged 18+[18]
18% Pfizer/BioNTech dose[6, 10]
Chile
2% Oxford/AstraZeneca + Currently no evidence that effectiveness of other administered vaccines may be
1% CanSino[17] significantly reduced by predominantly circulating variants[3]
73% Pfizer/BioNTech + Currently no evidence that administered vaccines’ effectiveness is significantly Anyone aged 18+ [21]
Germany
16% Oxford/AstraZeneca reduced by circulating VOC, if full vaccination course is taken[3, 4] Adolescents aged 12-17 with comorbidities, work-related
8% Moderna high risk of exposure or when living with people with a
3% Johnson&Johnson[19, 20] high risk who cannot be vaccinated themselves[12]
57% Sinopharm/Beijing - Limited evidence of potentially very small effectiveness shortly after first Sinopharm Anyone aged 18+[23, 24]
Seychelles
43% Oxford/AstraZeneca.[13, 22] dose[5]
+ Currently no evidence that effectiveness of other administered vaccines may be
significantly reduced by predominantly circulating variants[3]
61% Oxford/AstraZeneca + Currently no evidence that administered vaccines’ effectiveness is significantly Anyone aged 18+[26];
Kingdom
United
38% Pfizer/BioNTech reduced by circulating VOC, if full vaccination course is taken[3, 4] In Scotland anyone aged 30+[27]
1% Moderna[25]
75% Sinovac - Limited evidence of potentially very small effectiveness shortly after first Sinovac Anyone aged 18+[28]
Uruguay
24% Pfizer/BioNTech dose[6, 10]
1% Oxford/AstraZeneca[20] + Currently no evidence that effectiveness of other administered vaccines may be
significantly reduced by predominantly circulating variants[8, 9]COVID-19 Containment Measures, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage 4. Potential Factors in Incidence Surges in Bahrain, Chile, Seychelles, the United Kingdom and Uruguay Bahrain – According to a media report only 6% of those infected since the beginning of the pandemic in the country had been vaccinated. More specifically, only 2% of those who had become infected had been fully vaccinated with two doses and had completed 14 days post-vaccination, reportedly none requiring treatment. According to the same report, in Bahrain, no difference in vaccine type received was observed among individuals infected post-vaccination. Between January and mid-May 2021, 6% of those who died of COVID-19 had been vaccinated with two doses and completed 14 days post-second dose.[16] Chile – The surge in cases is attributed by some observers to loosened measures early on in the vaccination campaign, reduced compliance with COVID-19 containment measures, including masking and physical distancing, following the start of the vaccination campaign, as well as the spread of VOC P.1 (Gamma). Some observers also noted that risk communication by the government at the beginning of the vaccination campaign might have contributed to people taking less precautions. Media reports suggest that people with incomplete vaccination coverage may have complied less with protective behaviors. Results from a study in Chile on vaccine effectiveness showed that the Sinovac vaccine had little effectiveness immediately following just a single dose, with rising effectiveness after two and three weeks following the first dose.[5, 10, 11] Seychelles – Writing in mid-May 2021, media cited the Seychelles Ministry of Health in saying that 37% of active cases were people who had been fully vaccinated. WHO was investigating some cases that had occurred shortly after a first or second dose. WHO was cited in the media as stating that most COVID-19 cases during the surge had occurred in those who were not vaccinated or not fully vaccinated.[15] The president of Seychelles reported in the media that in the age group 18 to 60, 80% of those who were hospitalized had not been vaccinated. Further results of WHO looking into the surge in Seychelles are pending. By early May, no deaths were reported in COVID-19 cases that had been fully vaccinated.[22, 29] The Seychelles Ministry of Health is now considering administering a booster dose to vulnerable individuals.[15] United Kingdom – Sequencing data showed that the share of VOC B.1.617.2 (Delta) has increased to 91% of all cases in the country. According to Public Health England, incidence has increased in all age and ethnic groups, but test positivity has most notably increased in younger age groups.[30] It also reports increasing outbreaks in educational settings.[31] A study from 5 April to 16 May 2021 indicated that the predominantly used vaccines in the United Kingdom (Oxford/AstraZeneca and Pfizer/BioNTech) are effective against VOC B.1.617.2 (Delta), especially after 2 doses.[32] Therefore, the four UK nations are reducing the time span between the 1st and 2nd dose of any vaccine. For example, in England the time span has been reduced from 12 to 8 weeks.[27] Uruguay – According to media reports, the surge in COVID-19 cases in Uruguay might be attributable to VOC P.1 (Gamma) and loosening of COVID-19 containment measures, such as physical distancing.[33, 34] Also, lacking compliance with physical distancing has been reported. A study published in March reported that only one out of three people in Uruguay thought they would get infected with SARS-CoV-2 in the next six months.[35] A newspaper article reported recently released results of a population-based study on the effectiveness of administered vaccines by the government in Uruguay. These results show that a full vaccination cycle of Sinovac reduced deaths by 95%, ICU admissions by 92% and infections with SARS-CoV-2 by 61%. The effectiveness of Pfizer/BioNTech was also studied and showed 94% effectiveness at preventing ICU admissions and 78% effectiveness in preventing infection.[36]
1 COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
5. COVID-19 containment measures in Bahrain, Chile, Germany, Seychelles, the United Kingdom and Uruguay,
1 March – 23 June 2021
This section only reports on COVID-19 containment measures regarding school closures, international travel
and face coverings. For a full overview of COVID-19 containment measures in the countries between early March
and late June 2021, see the heatmap in Figure 2.1
School closures – were loosened slightly between April and May 2021 in Bahrain and more recently in
Seychelles. However, both countries have tightened this measure since then. School closures have been
loosened over time in Germany, the United Kingdom and Uruguay.
International travel measures – remain strict in all countries, with no loosening trend over time.
Face coverings – remain strictly required, with no change over time, in Bahrain and the United Kingdom.
In Germany and Uruguay, face coverings are required only in some public spaces, with no change in this
measure over time. In Chile, face covering measures were tightened from 1 May 2021 onwards and in Seychelles
from 1 June 2021 onwards, following a previous mix of loosening and tightening.
1
Due to the coding scheme applied by Our World in Data, the loosening and tightening of COVID-19 containment measures at the sub-
national level does not fully display in Figure 2. In the case of Chile, that means lifting of measures in March 2021 is not displayed in the
heatmap.COVID-19 Containment Measures, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
1 March 2021 1 April 2021 1 May 2021 1 June 2021 23 June 2021
School Closures Required (all levels) Recommended Required (some levels)
Workplace Closures Required (some levels)
Cancellation of Public Events Recommended cancellations Required cancellations
Restrictions on Public Gatherings > 1000 people 10-100 people 100-1000 people1 COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
Face Coverings Required in some public spaces Required in all public Required in some public Required in all public
spaces spaces spaces
Public Transport Closures Recommended closing (or reduce No measure Recommended closing (or
volume) reduced volume)
Restrictions on Internal Movement Recommended movement No measures Recommend movement
restrictions restriction
International Travel Controls Ban on high-risk-regions Screening Ban on high-risk regions
School Closures Required (all levels) Required (some levels) Recommended
Workplace Closures Required (all levels) Required (some levels)
Cancellation of Public Events Required cancellations Recommended
cancellations
United Kingdom
Restrictions on Public Gatherings2
COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
6. Synthesis
Surges in incidence in countries with high vaccination coverage have concerned decision makers. They
highlight the need for decision makers and publics to remain vigilant in spite of ongoing vaccination
campaigns.
Reliable data on what drove or continues to drive surges is not available for most countries. In particular, the
following kinds of data are lacking for most of the five countries or are not available in sufficient quality:
Age distribution of COVID-19 cases.
Vaccination status of COVID-19 cases.
High-quality genomic surveillance data on variants of concern.
Surges are possibly due to a combination of factors. These include:
Premature loosening of COVID-19 containment measures.
Reduced compliance with physical distancing requirements, including by individuals with incomplete
vaccination coverage.
Spread of variants of concern.
Surges in incidence provide important lessons in COVID-19 containment:
Unvaccinated population groups remain vulnerable even in countries with higher vaccination coverage.
This is indicated by Public Health England data on high incidence and increasing test positivity in
younger age groups.
COVID-19 containment measures should be upheld during vaccination campaigns, including to protect
unvaccinated and vulnerable individuals.
The recent surges in incidence have also provided insights regarding vaccine effectiveness:
The effectiveness of distributed vaccines in the six countries is generally not significantly reduced by
circulating variants of concern.
According to media reports, the majority of new cases during periods of surging incidence occurred in
unvaccinated individuals or in those who were not yet fully vaccinated.
Germany could consider the following recommendations:
Countries experiencing surges in COVID-19 incidence should investigate the age distribution and
vaccination status of cases. This could provide them with the evidence needed to adopt suitable
countermeasures. Countries should also share these data internationally to inform decision-making.
National vaccination campaigns should strive to reach unvaccinated individuals. Continued high
incidence worldwide entails a continued risk that further variants of concern may emerge and spread.
Therefore, vaccination campaigns should also be considered a global effort.
If countries lack evidence on variants of concern due to low genomic surveillance capacities, these
countries should be supported in building up that capacity.3
COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
7. Methodology and Evidence Rating
The epidemiological evidence presented in this report builds on public data collected from a variety of sources.
Weekly incidence and new deaths per 100,000 population were calculated by the report authors on the basis of
the dataset by Appel et al. from Our World in Data.[38] COVID-19 cases and deaths in the Our World in Data-
dataset stem from the Center for Systems Science and Engineering at Johns Hopkins University. Vaccination
coverage was calculated by the authors on the basis of the vaccination dataset from Our World in Data by
Mathieu et al.[2] Data on the prevalence of COVID-19 virus variants stems from analyses of public sources
conducted by the Public Health Intelligence Unit at Robert Koch Institute and was supplemented with
government sources. Data on COVID-19 containment measures stems from the Oxford COVID-19 government
response tracker by Hale et al.[24] Data on vaccine types administered and predominant vaccine types stems
from Our World in Data and was supplemented with media reports where no data from Our World in Data was
available. The percentage shares of administered vaccines types per country were calculated by the report
authors. Data on vaccination status of COVID-19 cases during phases of increasing incidence in the countries
mostly stems from media reports, due to a paucity of public government sources. Data on national vaccination
campaigns’ priority groups stems from government sources. Data on COVID-19 vaccine efficacy and
effectiveness stems from the World Health Organization’s Weekly Epidemiological Updates and other reports
and scientific publications.
Data on COVID-19 incidence, deaths rates and vaccination coverage was available for all countries. Data on
COVID-19 incidence stratified by age groups was only available for Germany and the United Kingdom. Data
on VOC circulation was available for five out of six countries. The representativeness and validity of data on
VOC is limited for Bahrain, Chile and Uruguay, good for Germany and very good for the United Kingdom
(England respectively). Data on vaccine types administered was available for all countries. Data quality on
vaccine effectiveness varies. Media reports were included in this report as data sources due to the lack of
scientific literature and evidence regarding the currents surges in these countries. Data on COVID-19
containment measures was available for all countries. Due to the coding scheme applied by the Oxford COVID-
19 government response tracker, containment policies at the sub-national level may not be fully represented in
the tracker’s data. It should be kept in mind that data from the Oxford COVID-19 government response tracker
do not reflect actual implementation and adherence to measures at the population level.4
COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
Appendix
A. Epidemiological Background
A.1 Weekly new COVID-19 cases per 100,000 population in Bahrain, Chile, Germany, Seychelles, the United
Kingdom, and Uruguay, 1 March – 29 June 2021 (Figure 1):
Weekly new cases per 100,000 population have been decreasing in Bahrain, Chile, Germany and Uruguay,
have been mostly stable in Seychelles and increasing in the United Kingdom. As of 27 June 2021, there are
5.21 weekly new COVID-19 cases per 100,000 population in Germany, 151.1 in the United Kingdom, 138.4 in
Bahrain, 157.38 in Chile, 470.73 in Uruguay (as of 20 June 2021) and 1009.76 in Seychelles.
A.2 Weekly new COVID-19 deaths per 100,000 population in Bahrain, Chile, Germany, Seychelles, the United
Kingdom, and Uruguay, 1 March – 29 June 2021 (Figure 1):
Weekly new deaths per 100,000 population have been increasing in Bahrain throughout May and in Seychelles
in June. In Germany, the rate has been declining through May and June and in Uruguay it began declining in
June. In Chile and the United Kingdom, rates have been stable throughout May and June. As of 29 June 2021,
weekly new deaths stand at 0.18 in the United Kingdom, 0.44 in Germany, 2.29 in Bahrain, 4.11 in Chile, 6.42
in Uruguay and 8.14 in Seychelles per 100,000 population.
A.3 Weekly incidence per 100,000 population by age group in Germany and England, 1 March - 29 June 2021
(Figure 3):
In Germany, incidence is declining across all age groups. Incidence is lowest in the oldest age groups 60-80+.
Incidence is rising in all age groups in England, but is highest in the age groups 10-39 (Figure 1). Public Health
England also reports that test positivity is most notably rising in younger age groups. The agency also reports
increasing outbreaks in educational settings.[30, 31]
A.4 Variants of concern:
In Bahrain, VOC B.1.617.2 (Delta) comprises 33.33%, VOC B.1.1.7 (Alpha) 24% and VOC B.1.351 (Beta) 4% of
sequenced cases. The country did not report any sequenced case of VOC P.1. (Gamma).[39] In Chile, VOCs
comprise 46.7% of sequenced cases between 22 December 2020 and 11 June 2021. VOC P.1 (Gamma) accounts
for 37.4% and VOC B.1.1.7 (Alpha) for 9.2% of all sequenced cases in this time frame.[40] In Germany, VOC
B.1.1.7 (Alpha) is prevalent in 74%, VOC B.1.617.2 (Delta) in 15% and both VOC B.1.351 (Beta) and VOC P.1
(Gamma) in less than 1% of all sequenced samples. The share of VOC B.1.617.2 (Delta) shows an increasing
trend.[41] In England, VOC B.1.617.2 (Delta) comprises 95% of sequenced cases.[42] In Uruguay, VOC P.1
(Gamma) comprises 99% of all sequenced cases.[43] No systematic data on circulating virus variants was
available for Seychelles.2
2
Data quality on COVID-19 variants varies greatly across countries. See “Methodology and Evidence Rating” in this report.5
COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
Figure 3: Weekly Incidence per 100,000 population by age group in Germany and England, weeks 9 – 25, 20216
COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
References
1. Our World in Data. Share of people vaccinated against COVID-19. 2021 22 June 2021]; Available
from: https://ourworldindata.org/explorers/coronavirus-data-
explorer?zoomToSelection=true&time=2021-03-
01&pickerSort=desc&pickerMetric=population&hideControls=true&Metric=People+vaccinated+%2
8by+dose%29&Interval=Cumulative&Relative+to+Population=true&Align+outbreaks=false&count
ry=DEU~SYC~GBR~BHR~CHL~URY.
2. Mathieu, E., et al., A global database of COVID-19 vaccinations. Nature Human Behaviour, 2021.
3. European Centres for Disease Prevention and Control, Assessing SARS-CoV-2 circulation, variants
of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update.
2021.
4. European Centre for Disease Prevention and Control, Implications for the EU/EEA on the spread
of the SARS CoV-2 Delta (B.1.617.2) variant of concern - 23 June 2021. 2021, ECDC: Stockholm.
5. Dyer, O., Covid-19: Chinese vaccines may need changes to improve efficacy, admits official. BMJ,
2021. 373: p. n969.
6. Vijay, S.L., Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves
Unanswered Questions, in Health Policy Watch. 2021.
7. World Health Organization. The Sinovac COVID-19 vaccine: What you need to know. 2021 23
June 2021]; Available from: https://www.who.int/news-room/feature-stories/detail/the-sinovac-
covid-19-vaccine-what-you-need-to-know.
8. World Health Organization. The Sinopharm COVID-19 vaccine: What you need to know. 2021 23
June 2021]; Available from: https://www.who.int/news-room/feature-stories/detail/the-sinopharm-
covid-19-vaccine-what-you-need-to-know.
9. World Health Organization, COVID-19 Weekly Epidemiological Update 43. 2021: Geneva.
10. Taylor, L., Covid-19: Spike in cases in Chile is blamed on people mixing after first vaccine shot.
BMJ, 2021. 373: p. n1023.
11. Guzmán Hormazábal, L. and D. Hirschfeld, Chile and Uruguay, from model to emergency, in
SciDev.Net. 2021.
12. Robert Koch Institut, COVID-19-Impfung für Kinder und Jugendliche im Alter von 12 bis 17
Jahren. Infoblatt für Kinder- und Jugendärzt:innen und Eltern. 2021.
13. Our World in Data. Source information country by country. 2021 23 June 2021]; Available from:
https://ourworldindata.org/covid-vaccinations#source-information-country-by-country.
14. Bahrain Ministry of Health. 12-17 year olds urged to take vaccine. 2021 23 June 2021]; Available
from: https://www.moh.gov.bh/COVID19/Details/4860.
15. Trofimov, Y. and S. Said, Bahrain, Facing a Covid Surge, Starts Giving Pfizer Boosters to
Recipients of Chinese Vaccine, in Wall Street Journal. 2021.
16. Bahrain News Agency, The National Medical Taskforce for Combating the Coronavirus (COVID-
19) provides an update on the COVID-19 response in the Kingdom in Bahrain News Agency. 2021.
17. Our World in Data. Which vaccines have been administered in each country? 2021 23 June 2021];
Available from: https://ourworldindata.org/covid-vaccinations#which-vaccines-have-been-
administered-in-each-country.
18. Chile Ministry of Health. Calendario de vacunación masiva contra COVID-19. 2021 23 June 2021];
Available from: https://www.minsal.cl/calendario-de-vacunacion-masiva-contra-covid-19/.
19. Paul-Ehrlich-Insitut. COVID-19-Impfstoffe. 2021 7 June 2021 21 June 2021]; Available from:
https://www.pei.de/DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html.
20. Our World in Data. Vaccination policies. 2021 25 May 2021]; Available from:
https://ourworldindata.org/covid-vaccinations#vaccination-policies.
21. Bundesministerium für Gesundheit. Zahlen, Fragen und Antworten zur COVID-19-Impfung. 28
June 2021 28 June 2021]; Available from:
https://www.bundesgesundheitsministerium.de/coronavirus/faq-covid-19-
impfung.html?fbclid=IwAR1zfmi-
0yZho5yKUtbl9FXXo5UdymqI1OVhF4tzkfNpWYVNzTbl1Xbz4vo.
22. Wee, S.-L., World’s Most Vaccinated Nation Is Spooked by Covid Spike, in New York Times. 2021.
23. Our World in Data. Vaccination policies. 2021 23 June 2021]; Available from:
https://ourworldindata.org/covid-vaccinations#vaccination-policies.
24. Hale , T., et al., A global panel database of pandemic policies (Oxford COVID-19 Government
Response Tracker). Nature Human Behaviour, 2021. 5: p. 529–538.7
COVID-19 Containment Measures Analysis, Issue 5 | Surges in COVID-19 incidence in countries with high vaccination coverage
25. Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of
Yellow Card reporting. 2021 17 June 2021 24 June 2021]; Available from:
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-
reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.
26. NHS. Coronavirus (COVID-19) vaccines. 2021 10 June 2021 21 June 2021]; Available from:
https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-
vaccine/.
27. Roxby, P., Covid: When will I get the vaccine?, in BBC. 2021.
28. Ministerio de Salud Pública. Etapas de la vacunación. 2021 25 March 2021 21 June 2021]; Available
from: https://www.gub.uy/ministerio-salud-publica/comunicacion/comunicados/grupos-
habilitados-para-vacunarse.
29. Sguazzin, A. and K. Bhuckory, Covid Cases Double in the World’s Most-Vaccinated Nation, in
Bloomberg. 2021.
30. Public Health England, Weekly national Influenza and COVID-19 surveillance report: Week 24
report (up to week 23 data). 2021.
31. Torjesen, I., Covid-19: Delta variant is now UK's most dominant strain and spreading through
schools. BMJ, 2021. 373(1445).
32. Public Health England. Vaccines highly effective against B.1.617.2 variant after 2 doses. 2021 22
May 2021 24 June 2021]; Available from: https://www.gov.uk/government/news/vaccines-highly-
effective-against-b-1-617-2-variant-after-2-doses.
33. Fernández Simon, M., Uruguay, once a coronavirus model, struggles against a deadly wave, in The
Washington Post. 2021.
34. Kirszenbaum, Q.a.B., Peter, Uruguay accused of squandering early Covid success amid deadly
surge, in The Guardian. 2021.
35. Taylor, L., Why Uruguay lost control of COVID, in Nature. 2021.
36. Desantis, D., Sinovac, Pfizer/BioNtech COVID-19 vaccines prove highly effective in Uruguay-
government, in Reuters. 2021.
37. Betsch, C., L.H. Wieler, and K. Habersaat, Monitoring behavioural insights related to COVID-19.
The Lancet, 2020. 395(10232): p. 1255-1256.
38. Appel, C., Beltekian, D., Gavrilov, D., Giattino, C., Hasell, J., Macdonald, B., Mathieu, E., Ortiz-
Ospina, E., Ritchie, H., Rodés-Guirao, L., Roser, M., Data on COVID-19 (coronavirus) by Our
World in Data. 2021.
39. Public Health Intelligence, Erlass ID 1839_42: Virusvarianten Bahrain. 2021, Robert Koch Institut:
Berlin.
40. Ministerio de Salud, Informe Epidemiológico. Curculación de variantes SARS-CoV-2 en Chile al 11
de junio de 2021. 2021, Departamenta de Epidemiología.
41. Robert Koch Institut, Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland. 2021.
42. Public Health England, SARS-CoV-2 variants of concern and variants under investigation in
England. Technical briefing 17. 2021.
43. Public Health Intelligence, Erlass 1849_40: Update Virusvarianten in ausgewählten Ländern.
2021, Robert Koch Institut: Berlin.You can also read
